T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union’s Innovative Medicines Initiative (IMI). The key objective of T2EVOLVE is to accelerate development and increase awareness and access of cancer patients to immunotherapy with immune cells that harbor a genetically engineered T-cell receptor (TCR) or synthetic chimeric antigen receptor (CAR). Simultaneously, T2EVOLVE aims to provide guidance on sustainable integration of these treatment into the EU healthcare system.

Explore T2EVOLVE’s hubs for patients and HCPs

One of the T2EVOLVE consortium's key objectives is to ensure patients have access to the best available care, and being able to provide relevant and reliable information for patients and healthcare professionals is vital in making sure this happens. Because of this,...

Join T2EVOLVE at the 6th European CAR T-cell meeting!

Join us at T2EVOLVE at the 6th European CAR T-cell Meeting in Valencia, Spain on 15-17 February 2024! This event is the biggest of its kind and contains a carefully crafted programme covering a wide range of topics, including deep science, translational research,...

CAR T-cell therapy

Engineered T-cell therapy is a revolutionary cancer treatment where a patient’s immune cells are reprogrammed to seek and destroy cancer cells. This transformative treatment has the potential to cure cancer with a single shot. This therapy is approved and available in the EU for the treatment of leukemia and has the potential to become a blockbuster therapy for other types of cancer, as well as infectious diseases and autoimmune diseases in the future.

For additional information on CAR T-cell technology please contact UKW.


Director CAR-T Research Program, Cellular Immunotherapy for Malignant Diseases Max Eder Research Group‚ CAR T-cell engineering, Universitätsklinikum Würzburg, Germany

Prof Michael Hudecek, MD

T2EVOLVE Project Coordinator

Scientific Director Bioproduction and Bioprocessing at Servier, and EFPIA project leader for T2EVOLVE IMI Consortium,
Suresnes Cedex, France 

Dr Hélène Negre, PhD

T2EVOLVE Project Leader


This project received funding from the innovative Medicines initiative 2 Joint Undertaking (JU) under grant agreement No 945393. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programe and EFPIA. More information can be found at:

Share This